Table 2A.
PK parameters of VIB4920 after administration of the first dose of VIB4920 and at steady state by study: Study 1
| Parameter | VIB4920 dose | |||
|---|---|---|---|---|
| 5 mg·kg−1 i.v. (N = 6) | 50 mg·kg−1 i.v. (N = 6) | 150 mg·kg−1 i.v. (N = 6) | 150 mg·kg−1 s.c. (N = 6) | |
| Tmax (days) | 0.02 (0.00) | 0.02 (0.00) | 0.02 (0.00) | 1.83 (0.75) |
| Cmax (μg·ml − 1) | 130 (15) | 1,560 (327) | 3,400 (200) | 1,720 (164) |
| Ctrough (μg·ml − 1) | 34 (7) | 262 (16) | 649 (81) | 858 (184) |
| AUCτ (μg·day·ml − 1) | 366 (44) | 3,930 (327) | 9,210 (906) | 8,720 (916) |
| Tmax ss (days) | 0.18 (0.40) | 0.02 (0.00) | 0.02 (0.00) | 1.33 (1.29) |
| Cmax ss (μg·ml − 1) | 193 (44) | 1,870 (179) | 4,240 (853) | 2,050 (323) |
| Ctrough ss (μg·ml−1) | 56 (11) | 412 (62) | 1,070 (339) | 1,140 (176) |
| AUCτ ss (μg·day·ml−1) | 745 (103) | 6,150 (26) | 14,700 (463) | 12,200 (1,560) |
| t 1/2 (days) | 6.19 (0.99) | 6.02 (0.20) | 5.55 (0.30) | 5.54 (0.21) |
Note. All values are presented as mean (SD).
Abbreviations: Cmax, maximum observed concentration; Ctrough, trough concentration; i.v., intravenous; PK, pharmacokinetic; s.c., subcutaneous; ss, steady state; Tmax, time of maximum observed concentration.